“CemiplimAb-Rwlc Survivorship and Epidemiology (CASE): A Prospective, Non-Interventional Study of the Safety and Effectiveness of Cemiplimab in Immunocompromised Immunosuppressed Patients With Advanced Cutaneous Squamous Cell Carcinoma at 2 Years’ Follow-Up”. SKIN The Journal of Cutaneous Medicine, vol. 10, no. 2, Mar. 2026, p. s756, https://doi.org/10.25251/hex0h755.